Brief: Sana Biotechnology Reports First Quarter 2023 Financial Results And Business Updates

Sana Biotechnology

08/05/2023 23:30

May 8 (Reuters) - Sana Biotechnology Inc  SANA.O :
    * SANA BIOTECHNOLOGY REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
AND BUSINESS UPDATES
    * SANA BIOTECHNOLOGY-IND CLEARED & ENROLLING PATIENTS IN
SC291
PHASE 1 CLINICAL TRIAL IN B-CELL MALIGNANCIES WITH INITIAL DATA
EXPECTED LATER THIS YEAR
    * GOAL TO SUBMIT INDS THIS YEAR FOR BOTH SC262 AND SG299 IN
HEMATOLOGIC CANCERS
    * CASH POSITION OF $355 MILLION EXPECTED TO SUPPORT
ACTIVITIES
THROUGH MULTIPLE DATA READOUTS AND LAST INTO 2025
    * EXPECT DATA LATER THIS YEAR FROM INVESTIGATOR-SPONSORED
TRIAL
WITH HYPOIMMUNE-MODIFIED PRIMARY HUMAN ISLET CELLS
    * QTRLY LOSS PER SHARE $0.43
    * QTRLY NON GAAP LOSS PER SHARE $0.43
    * Q1 EARNINGS PER SHARE VIEW $-0.45 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX11d0Pb 
Further company coverage:  SANA.O 

 ((Reuters.Briefs@thomsonreuters.com;))